Refine by
Toxicity Testing Suppliers & Manufacturers
5 companies found
Technologybased inNess Ziona, ISRAEL
Science in Action (SIA) is a boutique preclinical contract research organization (CRO) founded in 2010 by immunologist Raanan Margalit. SIA is GLP-accredited for toxicology studies in multiple areas. SIA has extensive experience in tailor-made ...
Technologybased inBoston, MASSACHUSETTS (USA)
We can create human tissues and organs using cells from our own bodies, paving the way to make us our own organ donors, reducing organ rejection and solve the problem with lack of donors. We can save lives with faster and more accurate methods for ...
Automated sorting and isolation of single spheroids and organoids. A game-changer in drug screening and other applications where standard 3D models will gradually replace traditional animal models. spheroONE is an innovative single large-particle ...
Technologybased inBuffalo Grove, ILLINOIS (USA)
BIOLIFE4D is a pioneering biotech company laser focused on leveraging advances in life sciences and tissue engineering to 3D bioprint a viable human heart suitable for transplant – lifesaving technology that gives patients the gift of time. With ...
Technologybased inHamburg, GERMANY
We are specialized in expanded primary cells and media (upcyte) as well as custom cell line development (ixcyte). Cells are our passion! If you are looking for a reliable partner for your project, we’ve got you covered. Our team of experienced ...
Keratinocytes represent the main cell type found in the epidermis and are thus attractive tools for studying wound healing and stress responses, as well as sensitizing properties and overall toxicity of test ...
Technologybased inRixensart, BELGIUM
CuraVac is a clinical-stage biotech company developing the medical and commercial potential of a revolutionary technique for the production of specific Therapeutic Vaccines for the treatment of autoimmune diseases. The company was founded by a ...
The MYASTERIX project (2013 – 2018) advanced a Therapeutic Vaccine candidate (designated orphan drug) indicated for myasthenia gravis (MG) to clinical proof of concept ...
